Vancomycin-induced linear IgA disease with autoantibodies to BP180 and LAD285

British Journal of Dermatology

Volumn 145, Issue 5, 2001, Pages 816-820

  Palmer, R A ^a   Ogg, G ^a,b   Allen, J ^a,b   Banerjee, A ^a,c   Ryatt, K S ^a,c   Ratnavel, R ^a,d   Wojnarowska, F ^a,b  

^a ROYAL SOUTH HANTS HOSPITAL   (United Kingdom)

^b OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c Birmingham Skin Centre   (United Kingdom)

^d STOKE MANDEVILLE HOSPITAL   (United Kingdom)

Author keywords

BP180; Drug eruption; LAD285; Linear IgA disease; Vancomycin

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; ANTIGEN; AUTOANTIBODY; BP180 ANTIBODY; BP180 ANTIGEN; CIPROFLOXACIN; COCODAMOL; COTRIMOXAZOLE; DALTEPARIN; DAPSONE; DIGOXIN; FUROSEMIDE; FUSIDATE SODIUM; HEPARIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; LACTULOSE; LAD285 ANTIBODY; LAD285 ANTIGEN; MORPHINE; OMEPRAZOLE; PENICILLIN G; PREDNISOLONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; VIGABATRIN;

AGED; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; HUMERUS SUPRACONDYLAR FRACTURE; LINEAR IMMUNOGLOBULIN A DISEASE; PRIORITY JOURNAL; SENNA; STAPHYLOCOCCUS INFECTION; URTICARIA; VARICOSIS;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNE DISEASES; CARRIER PROTEINS; COLLAGEN; CYTOSKELETAL PROTEINS; DRUG ERUPTIONS; FEMALE; HUMANS; IMMUNOGLOBULIN A; NERVE TISSUE PROTEINS; NON-FIBRILLAR COLLAGENS; SKIN; SKIN DISEASES, VESICULOBULLOUS; VANCOMYCIN;

EID: 0035166550     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2001.04492.x     Document Type: Article

References (39)

1. Drug-induced linear IgA disease: Target antigens are heterogeneous
2. Drug-induced linear IgA disease with antibodies to collagen VII
3. Vancomycin-induced linear IgA bullous dermatosis
4. Bullous drug eruption treated with amputation
5. Vancomycin-associated linear IgA dermatosis
6. Dermatoses a IgA lineaire medicamenteuses
7. Drug-induced linear IgA bullous dermatosis
8. Drug-induced linear IgA bullous dermatosis: Report of six cases and review of the literature
9. Linear IgA dermatosis related to vancomycin
10. Vancomycin-induced linear IgA bullous dermatosis (LABD)
11. Clinical, demographic, and immunohistologic features of vancomycin-induced linear IgA bullous disease of the skin. Report of 2 cases and review of the literature
12. Drug-induced linear IgA bullous dermatosis after vancomycin discontinuance in a patient with renal insufficiency
13. Vancomycin-induced linear IgA bullous disease
14. Linear IgA bullous dermatosis associated with vancomycin
15. The localization of the target antigens and antibodies in linear IgA disease is heterogeneous and dependent on the methods used
16. Identification of the target antigen in chronic bullous disease of childhood and linear IgA disease of adults
17. Linear IgA disease of adults: Association with lymphoproliferative malignancy and possible role of other triggering factors
18. Drug-induced linear immunoglobulin A disease
19. Adult linear IgA disease associated with an erythema multiforme-like drug reaction
20. Interleukin-2 associated linear IgA bullous dermatosis
21. Drug-induced bullous dermatosis with linear IgA deposits along the basement membrane
22. Amiodarone-induced linear IgA disease
23. Dermatose a IgA lineaire (DIAL) induite par penicilline G
24. Dermatose bulleuse avec depots lineaires d'IgA le long de la membrane basale au cours d'un traitement par l'interferon gamma et l'interleukine-2
25. Linear IgA bullous dermatosis related to lithium carbonate
26. The 97 kDa linear IgA bullous disease antigen is identical to a portion of the extracellular domain of the 180 kDa bullous pemphigoid antigen, BPAg2
27. Antigenic specificity of antibodies from patients with linear basement membrane deposition of IgA
28. A comparison of the expression of known basement membrane components with the linear IgA disease antigens using the novel substrate cylindroma
29. Linear IgA bullous dermatosis with IgA antibodies exclusively directed against the 180- or 230-kDa epidermal antigens
30. Linear IgA disease: Heterogeneity of antigens with regard to localisation and molecular weight between and within patients
31. The localization of target antigens and autoantibodies in linear IgA disease is variable: Correlation of immunogold electron microscopy and immunoblotting
32. 97-kDa linear IgA bullous dermatosis (LAD) antigen localizes to the lamina lucida of the epidermal basement membrane
33. LAD-1, the linear IgA bullous dermatosis autoantigen, is a novel 120-kDa anchoring filament protein synthesized by epidermal cells
34. Linear IgA bullous dermatosis of childhood with autoantibodies to a 230 kDa epidermal antigen
35. Type VII collagen is the antigen recognized by IgA anti-sublamina densa autoantibodies
36. Linear IgA bullous dermatosis with autoantibodies to a 290 kDa antigen of anchoring fibrils
37. A case of linear IgA bullous dermatosis with IgA anti-type VII collagen autoantibodies
38. Linear IgA disease with IgA antibodies directed against 200- and 280-kDa epidermal antigens
39. Adult linear IgA disease and chronic bullous disease of childhood: The association with human lymphocyte antigens Cw7, B8, DR3 and tumour necrosis factor influences disease expression